NewAmsterdam Pharma Company N.V.
NAMS
$16.34
$0.311.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -453.72% | 57.32% | 58.40% | -89.45% | -5.01% |
| Total Depreciation and Amortization | 82.14% | 47.37% | 26.67% | 15.38% | -7.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,437.10% | 1,107.14% | -100.82% | 597.23% | 17.27% |
| Change in Net Operating Assets | -28,600.00% | 100.19% | -43.88% | -208.54% | 258.69% |
| Cash from Operations | -199.80% | 76.84% | 1.14% | -65.09% | 29.59% |
| Capital Expenditure | 96.00% | 64.11% | 45.71% | -12,733.33% | 66.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -82,805.33% | 64.11% | 45.71% | -12,733.33% | 66.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 787,203.45% | -98.75% | -98.83% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 787,160.34% | -98.75% | -97.65% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -274.82% | 599.45% | 63.58% | -147.82% | 426.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,474.16% | 84.18% | -135.85% | 605.07% | 42.44% |